Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topical Insulin for Glaucoma
Sponsor: Stanford University
Summary
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Official title: Topical Insulin for Glaucoma and Optic Neuropathies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2022-04-01
Completion Date
2026-12-31
Last Updated
2025-11-25
Healthy Volunteers
No
Conditions
Interventions
Insulin, 4 units
Topical insulin 100 U/ml, 1 drop per day
Insulin, 20 units
Topical insulin 500 U/ml, 1 drop per day
insulin, 4 units twice daily
1 drop of low dose insulin twice daily.
insulin, 20 units twice daily
1 drop of high dose insulin twice daily
insulin, 4 units three times daily
1 drop of low dose insulin three times daily.
insulin, 20 units three times daily
1 drop of high dose insulin three times daily.
Locations (1)
Byers Eye Institute at Stanford University
Palo Alto, California, United States